HRT Financial’s Gyre Therapeutics GYRE Stock Holding History

HRT Financial’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,457	Closed	-$16K	–	2770
2023 Q1	$16K	Buy	+5,457	New	+$20.7K	﹤0.01%	2204
2021 Q4	–	Sell	-7,172	Closed	-$221K	–	3537
2021 Q3	$221K	Sell	7,172 -4,801	-40%	-$158K	﹤0.01%	2619
2021 Q2	$388K	Buy	+11,973	New	+$411K	﹤0.01%	1978

Other funds holding GYRE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

HRT Financial's GYRE Position: Q2 2023 in Review

HRT Financial sold out of Gyre Therapeutics (GYRE) in Q2 2023, closing a stake of 5,457 shares — an estimated $16K sold.

HRT Financial first reported a position in GYRE in Q2 2021 and held it in 3 quarters. The position peaked at $388K in Q2 2021. 28 funds tracked by Wall St. Rank hold GYRE as of Q2 2023.

HRT Financial reported no remaining Gyre Therapeutics position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 5,457 Gyre Therapeutics shares in Q2 2023, an estimated $16K.
HRT Financial first reported a position in Gyre Therapeutics in Q2 2021 and held it in 3 quarters.
HRT Financial's Gyre Therapeutics position peaked at $388K in Q2 2021.
28 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.